Primer, probe composition and kit for detecting H9 subtype AIV and IBV and application

By designing specific primer and probe compositions, combined with multiple fluorescence PCR technology, the problem of difficult to distinguish and detect H9 subtypes AIV and IBV in the prior art has been solved, and simultaneous detection and accurate diagnosis of multiple viruses have been achieved, improving the detection sensitivity and specificity.

CN118957158APending Publication Date: 2024-11-15CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENT
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411297204.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to quickly and accurately distinguish and detect two viruses, AIV and IBV, and especially when the virus mutations are frequent, it is difficult for existing methods to cover all strains or genotypes, resulting in difficulty in early diagnosis.

Method used

A primer and probe composition for detecting H9 subtypes AIV and IBV was designed. Multiple target genes were amplified simultaneously in the same PCR tube by multiple fluorescence PCR technology, and specific fluorescence probes and primers were combined to achieve the prevention of multiple viruses. At the same time, the detection avoids cross-reactions and improves the sensitivity of the detection.

Benefits of technology

A specific detection of H9 subtypes AIV and IBV is achieved, which can detect multiple branched viruses simultaneously, and does not cross-react with other common viruses. It has high detection sensitivity. The minimum detection volume of both viruses is 1 copy. Fast and accurate diagnosis methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957158A_ABST
    Figure CN118957158A_ABST
Patent Text Reader

Abstract

The invention provides a primer, a probe composition and a kit for detecting H9 subtype AIV (avian influenza virus) and IBV (infectious bursal virus) and application, and belongs to the technical field of fluorescence detection. According to the primer and probe composition capable of detecting the H9 subtype avian influenza virus and the avian infectious bronchitis virus, which is designed by the invention, SEQ ID NO.1-6 can be used for specifically detecting the H9 subtype avian influenza virus, the avian infectious bronchitis virus and various branch viruses of the H9 subtype avian influenza virus and the avian infectious bronchitis virus; cross reaction with other common viruses is avoided, the detection sensitivity is high, and the lowest detectable quantities of the two viruses are both 1 copy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of fluorescence detection, and in particular to a primer, a probe composition, a kit and applications for detecting H9 subtype AIV and IBV. Background Art

[0002] Avian influenza is an acute, highly contagious disease of poultry caused by influenza A virus of the Orthomyxoviridae family. Avian influenza virus (AIV) is a single-stranded, negative-sense RNA virus composed of eight independent RNA segments. It has numerous subtypes and frequent mutations. In addition to infecting poultry, AIV can also infect a variety of animals such as humans, pigs, and horses. Avian influenza viruses can be divided into 16 HA subtypes based on the antigenic differences in the hemagglutinin (HA) on the surface of their virus particles. The pathogenicity of different subtypes to the host varies significantly. Based on the difference in pathogenicity, AIV can be divided into highly pathogenic AIV and low pathogenic AIV. Among all HA subtypes, only some strains of the H5 and H7 subtypes are highly pathogenic to poultry, called highly pathogenic AIV, which can cause 100% mortality in chickens.

[0003] Among low-pathogenic AIVs, the H9 subtype has a wide range and high prevalence, with outbreaks occurring in many countries worldwide. Since the first H9 subtype AIV was isolated from chickens in 1994, outbreaks have occurred in most provinces in my country. H9 subtype AIV can not only cause respiratory symptoms and reduced egg production in chickens, but can also lead to immunosuppression, causing the spread of other diseases, and inflicting ongoing damage and significant economic losses on the poultry industry.

[0004] H9 subtype AIV can be genetically divided into two major clades: the North American lineage and the Eurasian lineage. The Eurasian lineage further gives rise to subgroups of viruses represented by BJ / 94-like, Y280-like, G1-like, Y439-like, and F / 98-like. According to the new subtype nomenclature system, H9 subtype AIV in my country is primarily classified as the H9.4.2 clade, which in turn evolves into clades H9.4.2.1 through H9.4.2.6. In recent years, H9 subtype AIV isolated in my country has primarily been classified as the H9.4.2.5 clade, which has further differentiated into five subclades, a through e. Therefore, detecting H9 subtype AIV from different clades is crucial to preventing widespread epidemics.

[0005] Infectious bronchitis (IBV) is an acute, highly contagious respiratory disease caused by the infectious bronchitis virus (IBV) that affects chickens of all ages. It primarily affects the respiratory, urogenital, and digestive systems of chickens, with symptoms including difficulty breathing and loose, white or watery stools. Affected chicks have a high mortality rate, while adult chickens experience decreased egg production, malformed eggs, and soft-shelled eggs. It is currently one of the most serious viral infections affecting my country's poultry industry and is present in nearly every poultry-raising country worldwide.

[0006] There are numerous IBV serotypes, with over 30 reported to date. Different serotypes vary significantly in virulence, pathogenicity, and tissue tropism, and there is little or no cross-immunity between them. In recent years, new serotypes have emerged continuously as the virus continues to mutate. However, because serotyping only describes differences in IBV neutralizing antigenic sites and does not reflect genomic variation, its practical detection applications are limited.

[0007] With advances in molecular biology techniques, phylogenetic classification of IBV isolates has begun, based on the S1 gene, to categorize IBV isolates into nine genotypes and 38 lineages. Genotype 1 encompasses 30 distinct viral lineages (tentatively designated GI-1 to GI-30), while each of the remaining genotypes consists of a single viral lineage. Genotyping has become the most commonly used method for classifying IBV isolates.

[0008] Epidemiological surveys show that there are many genotypes of IBV in China, including GI (GI-1, GI-2, GI-3, GI-4, GI-5, GI-6, GI-7, GI-13, GI-16, GI-18, GI-19, GI-22), GVI-1 and GVII-1.

[0009] H9 subtype AIV and IBV are two common pathogens in chickens. Both can cause respiratory symptoms and decreased egg production. The clinical symptoms of these two diseases are similar, making direct differentiation difficult clinically. Laboratory techniques are required for differentiation. Virus isolation and serological testing remain the most commonly used methods for diagnosing avian influenza and infectious bronchitis.

[0010] Early and rapid detection and diagnosis are undoubtedly prerequisites for controlling these diseases. However, these methods are cumbersome and complex to operate, making it difficult to quickly diagnose the two pathogens, which is very unfavorable for the prevention and treatment of the two diseases. Polymerase chain reaction (PCR) is an in vitro gene amplification technology that can amplify a certain gene segment millions of times in a few hours. This technology has strong specificity and high sensitivity. Fluorescent PCR is based on PCR and uses fluorescent signals to monitor the PCR amplification process and quantitatively analyze specific DNA sequences in the test sample. It is superior to general PCR in terms of sensitivity, specificity, and amplification efficiency.

[0011] The basic principles of fluorescent PCR include dye method and TaqMan probe method. The dye method uses double-linked DNA cross-linking fluorescent dyes, such as Green I, this dye can bind to double-stranded DNA non-specifically and emit a strong fluorescent signal when bound to double-stranded DNA. Green I can bind to any double-stranded DNA and cannot distinguish between primer dimers or non-specific amplification products. Therefore, melting curve analysis is generally required to exclude false positives.

[0012] The TaqMan probe method utilizes a specific fluorescent probe labeled with a reporter group and a quencher group at each end. During PCR amplification, the 5'-3' exonuclease activity of Taq DNA polymerase hydrolyzes the probe, separating the reporter and quencher groups and generating fluorescence. This method offers high specificity and can accurately detect the amplification of specific DNA sequences.

[0013] Currently, most PCR methods are for separate detection of H9 subtype AIV or IBV. Moreover, as the virus continues to mutate, existing methods are difficult to cover all strains or genotypes. There is an urgent need to establish a rapid detection method that can detect all strains or genotypes and distinguish between the two diseases, providing a sensitive, fast and practical method for early rapid diagnosis of clinical diseases.

[0014] The reaction principle, reagents, and procedures of multiplex fluorescent PCR technology are identical to those of conventional fluorescent PCR. However, compared with multiple single-target fluorescent PCR, multiplex fluorescent PCR offers the following significant advantages: high efficiency, enabling simultaneous amplification of multiple target genes within the same PCR tube or typing of target genes with multiple types; systematicity, making multiplex fluorescent PCR well-suited for the simultaneous detection of multiple pathogens; and economical simplicity, enabling the simultaneous amplification of multiple target genes within the same reaction tube, significantly saving time, reagents, and funds, providing more accurate diagnostic information for clinical practice. Since its initial description in 1988, multiplex fluorescent PCR has been successfully applied as a rapid clinical and laboratory screening technique in numerous fields, such as analysis of gene deletions, mutations, and polymorphisms, RNA detection, and genome sequencing.

[0015] The key to the success of any type of fluorescent PCR lies in the proper design of primers and probes. Appropriate primers and probes are crucial for determining the specificity and sensitivity of fluorescent PCR amplification. Multiplex fluorescent PCR places even stricter demands on primers to enable simultaneous detection of multiple pathogens. In addition to requiring similar annealing temperatures for each primer pair and similar Tm values ​​for each probe, the primer and probe sequences must be free of stable dimers, hairpin structures, and nonspecific binding. This ensures that the components within the system effectively amplify their respective target fragments without interfering with each other, which could affect amplification specificity and sensitivity.

[0016] Although there are many software programs available to assist in primer and probe design, automated search results are not ideal. To obtain highly effective primers, in addition to automated searches, various software programs must be used in conjunction with the software. While software can be helpful in primer and probe design, its limitations are also significant. First, software-designed primers and probes search for optimal regions along the full-length sequence. However, due to the frequent genomic mutations of RNA viruses, these regions may not be the most conserved or appropriate. Second, manual analysis and hands-on experience are essential for primer and probe design. A reliable multiplex fluorescence PCR detection system must undergo extensive testing, verification, and screening by scientific and technical personnel. Therefore, selecting appropriate primers and probes is crucial for the simultaneous detection of H9 subtype AIV and IBV. Summary of the Invention

[0017] The purpose of the present invention is to provide a primer, a probe composition, a kit and an application for detecting H9 subtype AIV and IBV, which can specifically detect H9 subtype AIV and IBV, as well as multiple branches of H9 subtype AIV and IBV, do not cross-react with other common viruses, and have high detection sensitivity.

[0018] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0019] The present invention provides a primer and probe combination for detecting H9 subtype AIV and IBV. The primer and probe combination for detecting H9 subtype AIV and IBV comprises a primer pair and a probe for detecting H9 subtype AIV, and a primer pair and a probe for detecting IBV.

[0020] Preferably, the primer pair for detecting H9 subtype AIV includes the upstream primer H9-1 shown in SEQ ID NO.1 and the downstream primer H9-2 shown in SEQ ID NO.2; the probe for detecting H9 subtype AIV is H9-P shown in the sequence SEQ ID NO.3; the primer pair for detecting IBV includes the upstream primer IBV-1 shown in SEQ ID NO.4 and the downstream primer IBV-2 shown in SEQ ID NO.5; the probe for detecting IBV is IBV-P shown in the sequence SEQ ID NO.6.

[0021] Preferably, the probes for detecting H9 subtype AIV are labeled with carboxyfluorescein FAM at the 5' end and with a quencher group BHQ1 at the 3' end; the probes for detecting IBV are all labeled with carboxyfluorescein CY5 at the 5' end and with a quencher group BHQ2 at the 3' end.

[0022] The present invention also provides a dual fluorescence detection kit, which includes a primer and probe combination for detecting H9 subtype AIV and IBV.

[0023] The present invention also provides an application of a dual fluorescence detection kit in the preparation of products for detecting H9 subtype AIV and IBV.

[0024] The present invention also provides a method for detecting H9 subtype AIV and IBV using a primer and probe combination for detecting H9 subtype AIV and IBV. The reaction system of the detection method is:

[0025] 2X fluorescent RT-PCR buffer 10.0 μL, reverse transcriptase and reverse transcriptase inhibitor 0.4 μL, DNA polymerase 0.4 μL, double-distilled water 2.4 μL, primers H9-1 and H9-2 0.9 μL each, IBV-1 and IBV-2 0.8 μL each, probes H9-P 0.6 μL, IBV-P 0.8 μL, and sample RNA template 2.0 μL to be tested;

[0026] The reaction procedure is:

[0027] The first stage was 42°C / 5 min; the second stage was 95°C / 30 s; the third stage was 95°C / 5 s, and fluorescence was collected at 58°C / 30 s for 40 cycles.

[0028] The advantages of the primer and probe combination for detecting H9 subtype AIV and IBV of the present invention compared with the prior art are as follows:

[0029] The primer and probe combinations designed in the present invention for detecting H9 subtype AIV and IBV (SEQ ID NOs. 1-6) can specifically detect H9 subtype AIV and IBV, as well as multiple clades of H9 subtype AIV and IBV, without cross-reacting with other common viruses. They also exhibit high sensitivity, with a minimum detectable concentration of 1 copy for both viruses. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0031] Figure 1 The results of dual fluorescence RT-PCR amplification of H9 subtype AIV and IBV in Example 1 are shown; wherein, 1: fluorescence RT-PCR amplification curve of H9 subtype AIV; 2: fluorescence RT-PCR amplification curve of IBV; 3-15: AIV H1, H2, H3, H4, H5, H6, H7, H10, H11, H12, H13 subtype strains, infectious bursal disease virus (IBDV) B87, infectious laryngotracheitis virus (ILTV) vaccine strain, Newcastle disease virus (NDV) Lasota strain, and normal chicken tissue nucleic acid controls;

[0032] Figure 2 The sensitivity amplification results of the dual fluorescence RT-PCR for H9 subtype AIV and IBV in Example 2 are shown in Table 2; 1: is 10 4 Copies / reaction, 2:10 3 Copies / reactions, 3:10 2 Copies / reactions, 4:10 1 Copies / reactions, 5:10 0 copy / react;

[0033] Figure 3 The sensitivity amplification results of the dual fluorescence RT-PCR for IBV detection of H9 subtype AIV and IBV in Example 2; where 1: is 10 4 Copies / reaction, 2:10 3 Copies / reactions, 3:10 2 Copies / reactions, 4:10 1 Copies / reactions, 5:10 0 copy / react;

[0034] Figure 4The detection spectrum of H9 virus subtype AIV and IBV dual fluorescence RT-PCR in Example 3 for different branches;

[0035] Figure 5 This is the detection spectrum of H9 subtype AIV and IBV dual fluorescence RT-PCR for common IBV genotypes in China in Example 3;

[0036] Figure 6 The results of clinical testing in Example 4 are shown. DETAILED DESCRIPTION

[0037] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0038] It should be understood that the terms described herein are intended only to describe particular embodiments and are not intended to limit the present invention. In addition, for numerical ranges herein, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Each smaller range between any intermediate value within a stated value or stated range and any other stated value or intermediate value within the stated range is also encompassed by the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded within the scope.

[0039] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of any conflict with any incorporated document, the contents of this specification shall prevail.

[0040] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from the description of the invention. The description and examples are intended to be exemplary only.

[0041] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0042] The primer pairs for detecting H9 subtype AIV provided by the present invention include:

[0043] H9-1 (SEQ ID NO.1): 5'-GGTCAAACTGGAATCTGAAG-3';

[0044] H9-2 (SEQ ID NO.2): 5'-CATTAGACATGGCCCAGA-3';

[0045] The probe for detecting H9 subtype AIV provided by the present invention is:

[0046] H9-P (SEQ ID NO. 3): 5'-AAGGCAGCAAACCCCATTGCAA-3', the 5' end of the probe is labeled with carboxyfluorescein FAM, and the 3' end is labeled with a quencher group BHQ1.

[0047] The primers for detecting IBV provided by the present invention include:

[0048] IBV-1 (SEQ ID NO.4): 5'-ACAAGGTCGGCTATACGACG-3';

[0049] IBV-2 (SEQ ID NO.5): 5'-CTCCCTGTTTTAGGCTTGAA-3';

[0050] The probe for detecting IBV provided by the present invention is:

[0051] IBV-P (SEQ ID NO. 6): 5'-CTGGTGGTGTTTAGTGAGCAGACATAC-3', the 5' end of the probe was labeled with carboxyfluorescein CY5, and the 3' end was labeled with a quencher group BHQ2.

[0052] Example 1

[0053] Example 1 of the present invention detects the specificity of the primer and probe combination of H9 subtype AIV and IBV, specifically comprising the following steps:

[0054] The nucleic acid DNA / RNA of the avian influenza virus H1, H2, H3, H4, H5, H6, H7, H9, H10, H11, H12, and H13 subtypes identified and preserved by the China Animal Health and Epidemiology Center, IBV H52, infectious bursal virus (IBDV) B87, infectious laryngotracheitis virus (ILTV) vaccine strain, and Newcastle disease virus (NDV) Lasota strain of the above viruses and normal chicken tissues were extracted using commercial kits to obtain the sample DNA / RNA templates to be tested.

[0055] The detection was carried out according to the following reaction system:

[0056] 2X fluorescent RT-PCR buffer 10.0 μL, reverse transcriptase and reverse transcriptase inhibitor 0.4 μL, DNA polymerase 0.4 μL, double-distilled water 2.4 μL, primers H9-1 and H9-2 0.9 μL each, IBV-1 and IBV-2 0.8 μL each, probes H9-P 0.6 μL, IBV-P 0.8 μL, and sample RNA template 2.0 μL to be tested;

[0057] The reaction procedure is:

[0058] The first stage was 42°C / 5 min; the second stage was 95°C / 30 s; the third stage was 95°C / 5 s, 58°C / 30 s (collecting fluorescence), for 40 cycles.

[0059] Figure 1 The results showed that H9 subtype AIV and IBV nucleic acids showed fluorescence amplification curves, while other common avian viruses and normal chicken tissue nucleic acids did not show amplification curves. This shows that the primer and probe combination for detecting H9 subtype AIV and IBV of the present invention can specifically detect H9 subtype AIV and IBV and does not cross-react with other common viruses.

[0060] Example 2

[0061] Example 2 of the present invention detects the sensitivity of the primer and probe combination of H9 subtype AIV and IBV, specifically comprising the following steps:

[0062] The amplified products of H9-1 and H9-2, IBV-1 and IBV-2 primers were connected to the T vector and then transcribed into cRNA in vitro. The nucleic acid concentration was determined and the copy number was calculated. Then, the cRNA was diluted 10-fold to 5 × 10 5 , 5×10 4 , 5×10 3 , 5×10 2 , 5×10 1 , 5×10 0 , 5×10 -1 copies / μL.

[0063] According to the reaction system of Example 1, 2 μL of the diluted nucleic acid was used as a template, and the reaction and detection were carried out according to the reaction procedure of Example 1. The results are as follows. Figure 2 shown.

[0064] Figure 2 and Figure 3 The results showed that the primer and probe combination designed by the present invention had high sensitivity for detecting H9 subtype AIV and IBV, and the minimum detection amount of both viruses was 1 copy.

[0065] Example 3

[0066] Example 3 of the present invention detects the detection spectrum of the primer and probe combination of H9 subtype AIV and IBV, which specifically includes the following steps:

[0067] The nucleic acids and RNA of the H9 subtype avian influenza viruses and normal chicken tissues were extracted using commercial kits to obtain DNA / RNA templates for the samples to be tested, including one strain each of the 10 clades of H9 subtype avian influenza viruses H9.4.2.1, H9.4.2.2, H9.4.2.3, H9.4.2.4, H9.4.2.6, H9.4.2.5a, H9.4.2.5b, H9.4.2.5c, H9.4.2.5d, and H9.4.2.5e, and one strain each of 17 genotypes of IBV, including GI-1, GI-2, GI-3, GI-4, GI-5, GI-6, GI-7, GI-13, GI-16, GI-18, GI-19, GI-22, GI-25, GI-28, GI-29, GVI-1, and GVII-1, identified and preserved by the China Animal Health and Epidemiology Center.

[0068] The reaction was carried out according to the reaction system and reaction procedure described in Example 1 and the results were as follows. Figure 3 shown.

[0069] Figure 4 and Figure 5 It is shown that the primer and probe composition of the present application for detecting H9 subtype AIV and IBV can detect the currently popular H9 subtype AIV (h9.4.2.1, h9.4.2.2, h9.4.2.3, h9.4.2.4, h9.4.2.6, h9.4.2.5a, h9.4.2.5b, h9.4.2.5c, h9.4.2.5d, h9.4.2.5e) and common IBV genotypes (GI-1, GI-2, GI-3, GI-4, GI-5, GI-6, GI-7, GI-13, GI-16, GI-18, GI-19, GI-22, GI-25, GI-28, GI-29, GVI-1 and GVII-1).

[0070] Example 4

[0071] Example 4 of the present invention uses the primer and probe combination of the present invention that can detect H9 subtype AIV and IBV to carry out clinical testing, specifically comprising the following steps:

[0072] A total of 182 throat swab samples were collected from various poultry at a live poultry market in a certain province. The swabs were placed in 1.0 mL of PBS (pH 7.0-7.4, 0.01 mol / L). The nucleic acid RNA of the samples was extracted using a commercial kit to obtain the sample DNA / RNA template to be tested.

[0073] The reaction was carried out according to the reaction system and reaction procedure described in Example 1 and the results were as follows. Figure 4 shown.

[0074] Figure 6 The results showed that among the 182 samples, 80 were positive for H9 subtype AIV nucleic acid, 76 were positive for IBV nucleic acid, and 32 were positive for both H9 subtype AIV and IBV nucleic acid, indicating mixed infection. The results show that this kit can quickly and accurately identify H9 subtype AIV and IBV and has good application prospects.

[0075] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. A primer and probe combination for detecting H9 subtype AIV and IBV, characterized in that: The primer and probe combination capable of detecting H9 subtype AIV and IBV comprises a primer pair and a probe for detecting H9 subtype AIV, and a primer pair and a probe for detecting IBV.

2. The primer and probe composition for detecting H9 subtype AIV and IBV according to claim 1, characterized in that: The primer pair for detecting H9 subtype AIV includes the upstream primer H9-1 shown in SEQ ID NO.1 and the downstream primer H9-2 shown in SEQ ID NO.2; the probe for detecting H9 subtype AIV is H9-P shown in the sequence SEQ ID NO.3; the primer pair for detecting IBV includes the upstream primer IBV-1 shown in SEQ ID NO.4 and the downstream primer IBV-2 shown in SEQ ID NO.5; the probe for detecting IBV is IBV-P shown in the sequence SEQ ID NO.

6.

3. The primer and probe composition for detecting H9 subtype AIV and IBV according to claim 2, characterized in that: The probe for detecting H9 subtype AIV is labeled with carboxyfluorescein FAM at the 5' end and with a quencher group BHQ1 at the 3' end; the probe for detecting IBV is labeled with carboxyfluorescein CY5 at the 5' end and with a quencher group BHQ2 at the 3' end.

4. A dual fluorescence detection kit, characterized in that: The dual fluorescence detection kit comprises the primer and probe combination for detecting H9 subtype AIV and IBV according to any one of claims 1 to 3.

5. Use of the dual fluorescence detection kit as claimed in claim 4 in preparing products for detecting H9 subtype AIV and IBV.

6. A method for detecting H9 subtype AIV and IBV using the primer and probe combination for detecting H9 subtype AIV and IBV according to any one of claims 1 to 3, characterized in that: The reaction system of the detection method is: 2X fluorescent RT-PCR buffer 10.0 μL, reverse transcriptase and reverse transcriptase inhibitor 0.4 μL, DNA polymerase 0.4 μL, double distilled water 2.4 μL, primers H9-1, H9-2 0.9 μL each, IBV-1, IBV-2 0.8 μL each, probes H9-P 0.6 μL, IBV-P 0.8 μL, sample RNA template to be tested 2.0 μL; The reaction procedure is: The first stage was 42°C / 5 min; the second stage was 95°C / 30 s; the third stage was 95°C / 5 s, and the fluorescence was collected at 58°C / 30 s for 40 cycles.

Citation Information

Cited By

  • Primer for detecting and distinguishing genotype of infectious bronchitis virus and application

    CN121065409A

  • Primer probe composition and kit for detecting H9 subtype AIV, NDV virulent strain and IBV and application

    CN121592812A

  • Primer probe composition and kit for detecting H9 subtype AIV (avian influenza virus), NDV (Newcastle Disease Virus) and IBV (Infectious Bursal Virus) and application

    CN121653296A